Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05558345 · ClinicalTrials.gov registry record · NA

Expression of Stress Markers During Meth Treatment (EXPRESS+)

A NA study of HIV and Substance-Related Disorders, sponsored by University of California, Los Angeles.

Recruiting
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT05558345 is a NA study of HIV and Substance-Related Disorders that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 55 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05558345, a NA study of HIV and Substance-Related Disorders, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Interventions

  • BEHAVIORAL Contingency Management

Study Locations (1)

California

  • UCLA Vine Street Clinic - Los Angeles

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2022-09-01
Est. Completion 2026-03-31
Phase NA

What the Registry Record Tells You About NCT05558345

The ClinicalTrials.gov registry entry for NCT05558345 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Contingency Management is the first listed.

NCT05558345 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05558345 about?

NCT05558345 is a clinical study titled "Expression of Stress Markers During Meth Treatment (EXPRESS+)". This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use diso...

What is the current status of trial NCT05558345?

This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2022-09-01. Estimated completion is 2026-03-31.

What conditions does trial NCT05558345 study?

This clinical trial studies the following conditions: HIV, Substance-Related Disorders.

What interventions are being tested in trial NCT05558345?

The interventions under investigation include: Contingency Management (BEHAVIORAL).

Who is sponsoring clinical trial NCT05558345?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05558345 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.